Lilly joins Atai and Beckley Psytech in betting on mebufotenin as a depression treatment, signaling deeper pharmaceutical interest in short-acting psychedelic drugs

Mebufotenin has become a new target in the pharmaceutical race to develop psychedelic-inspired treatments for depression, with Eli Lilly moving to acquire a program from Atai Life Sciences and Beckley Psytech. The deal points to rising interest in short-acting compounds that might fit more easily into conventional drug development and clinical care than longer psychedelic sessions. Atai and Beckley had been advancing mebufotenin for depressive disorders, positioning it as a potential alternative within the emerging mental health pipeline. Lilly's move suggests large drugmakers see strategic value in psychedelic assets that can be scaled, patented, and integrated into mainstream psychiatry. The acquisition also reflects broader consolidation across the psychedelic sector. Capital pressure on smaller developers and growing demand for differentiated depression treatments are pushing early innovators and major pharmaceutical companies into closer alignment.